Skip to main content
. Author manuscript; available in PMC: 2021 Sep 10.
Published in final edited form as: J Control Release. 2020 Jul 3;325:198–205. doi: 10.1016/j.jconrel.2020.06.030

Figure 2.

Figure 2.

PBD-based DLNPs exhibited high delivery potency of luciferase mRNA in cells. a) Luminescence intensity of IGROV1 cells treated with different DLNP formulations containing luciferase mRNA 24 h after transfection (25 ng mRNA per well; mean ± s.d., n = 3). Control: untreated cells. b) C57BL/6 mice were injected intravenously with different DLNPs formulated with PEGDMG at a dose of 0.1 mg kg−1 Luc mRNA and imaged 6 h after injection. c) Z-Average size and zeta potential of DLNPs formulated with 4.76 % PEGDMG, 3.23% PEG2k5a, and 3.23% PEG2k5c, respectively. d) DLS size of 4A3-SC8&PEG2k5c DLNP. e) TEM image of 4A3-SC8&PEG2k5c DLNP.